Toward precision in psoriatic arthritis: addressing the challenge of difficult-to-treat disease

Rubén Queiró; Sara Alonso

doi:10.1080/1744666x.2025.2575355

October 13, 2025Expert Review of Clinical Immunology

Toward precision in psoriatic arthritis: addressing the challenge of difficult-to-treat disease

View Full Paper

Ask AI

Bookmark

Share

Key Points

Difficult-to-treat psoriatic arthritis presents ongoing treatment challenges, impacting patient health and wellbeing.
Persistent disease burden occurs even after multiple targeted therapies for psoriatic arthritis, indicating unmet needs.
Identifying the characteristics of difficult-to-treat psoriatic arthritis is crucial for developing effective therapies.
The study emphasizes the necessity for tailored therapeutic strategies to improve outcomes for difficult-to-treat psoriatic arthritis.

Implication

This analysis highlights the challenges in managing difficult-to-treat psoriatic arthritis, suggesting new therapeutic strategies.

Abstract

Introduction Difficult-to-treat psoriatic arthritis (D2T-PsA) is increasingly recognized as a complex clinical entity characterized by persistent disease burden despite multiple targeted therapies. Its identification is essential to improve patient outcomes and to guide the development of new therapeutic strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Queiró et al. (2025) studied this question.

synapsesocial.com/papers/68f01110f081da0584b56958 https://doi.org/10.1080/1744666x.2025.2575355

View Full Paper

Ask AI

Bookmark

Share

Toward precision in psoriatic arthritis: addressing the challenge of difficult-to-treat disease

Key Points

Implication

Abstract

Discussion

Cite This Study

Toward precision in psoriatic arthritis: addressing the challenge of difficult-to-treat disease

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading